NewsBite

Cancer-free after 12 years: Why you’re hearing the C-word more often

Cancer-free after 12 years: Why you’re hearing the C-word more often

Two ASX-listed ventures are among the companies now investing billions of dollars to develop an emerging immunotherapy treatment known as CAR-T. From the upcoming Innovation issue, out on February 26.

Biotech entrepreneur Paul Hopper at KPD Australia. His latest venture, Chimeric, has begun a phase-one clinical trial of its CAR-T therapy in the US. Louie Douvis

Yolanda RedrupRich List Editor

Subscribe to gift this article

Gift 5 articles to anyone you choose each month when you subscribe.

Subscribe now

Already a subscriber?

Laurie Adami was 45 when she began “feeling crummy”, exhausted and plagued with constant sinus infections.

It was 2006 and the high-flying tech executive, who was juggling her career while raising a young son, was told by doctors her blood tests looked normal. Given she was a busy working mum, they opined, it was hardly surprising she was tired at the end of the day.

Loading...

Subscribe to gift this article

Gift 5 articles to anyone you choose each month when you subscribe.

Subscribe now

Already a subscriber?

Read More

Yolanda Redrup
Yolanda RedrupRich List EditorYolanda Redrup is the editor of the AFR Rich List. She previously reported on technology, healthcare and Street Talk. Connect with Yolanda on Twitter. Email Yolanda at yolanda.redrup@afr.com

Latest In Technology

Fetching latest articles

Original URL: https://www.afr.com/technology/cancer-free-after-12-years-why-you-re-hearing-the-c-word-more-often-20201217-p56ohe